DZ Bank AG restated their neutral rating on shares of Qiagen N.V. (NASDAQ:QGEN) in a research note issued to investors on Monday.

Other research analysts have also recently issued research reports about the company. TheStreet upgraded Qiagen N.V. from a c rating to a b rating in a research report on Monday, June 5th. Evercore ISI raised their price target on Qiagen N.V. from $30.00 to $31.50 and gave the company an outperform rating in a research report on Thursday, May 4th. Commerzbank Ag restated a buy rating on shares of Qiagen N.V. in a research report on Monday, May 15th. BidaskClub cut Qiagen N.V. from a strong-buy rating to a buy rating in a research report on Saturday, June 10th. Finally, Barclays PLC restated an overweight rating and issued a $37.00 price target (up previously from $33.00) on shares of Qiagen N.V. in a research report on Monday, July 17th. Nine analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of Hold and an average price target of $33.17.

Shares of Qiagen N.V. (NASDAQ:QGEN) opened at 32.17 on Monday. Qiagen N.V. has a 52 week low of $24.86 and a 52 week high of $35.26. The firm has a market cap of $7.34 billion, a PE ratio of 98.38 and a beta of 1.14. The firm’s 50-day moving average is $32.58 and its 200 day moving average is $31.43.

Qiagen N.V. (NASDAQ:QGEN) last announced its quarterly earnings results on Thursday, July 27th. The company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.02. Qiagen N.V. had a return on equity of 11.04% and a net margin of 5.44%. The business had revenue of $349 million during the quarter, compared to analysts’ expectations of $353.09 million. During the same quarter last year, the business posted $0.24 earnings per share. The business’s revenue for the quarter was up 4.4% on a year-over-year basis. Equities research analysts forecast that Qiagen N.V. will post $1.22 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Qiagen N.V.’s (QGEN) “Neutral” Rating Reiterated at DZ Bank AG” was reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.watchlistnews.com/qiagen-n-v-s-qgen-neutral-rating-reiterated-at-dz-bank-ag/1535488.html.

Several hedge funds have recently bought and sold shares of QGEN. BlackRock Inc. raised its stake in Qiagen N.V. by 8,793.4% in the first quarter. BlackRock Inc. now owns 7,839,636 shares of the company’s stock worth $227,114,000 after buying an additional 7,751,485 shares during the last quarter. Legal & General Group Plc raised its stake in shares of Qiagen N.V. by 2,651.3% in the first quarter. Legal & General Group Plc now owns 1,896,813 shares of the company’s stock worth $16,690,000 after buying an additional 1,827,871 shares during the last quarter. Edmond DE Rothschild Holding S.A. acquired a new stake in shares of Qiagen N.V. during the first quarter worth about $46,480,000. Neuberger Berman Group LLC acquired a new stake in shares of Qiagen N.V. during the first quarter worth about $31,875,000. Finally, Renaissance Technologies LLC raised its stake in shares of Qiagen N.V. by 182.9% in the first quarter. Renaissance Technologies LLC now owns 1,514,898 shares of the company’s stock worth $43,890,000 after buying an additional 979,498 shares during the last quarter. 63.01% of the stock is currently owned by institutional investors and hedge funds.

Qiagen N.V. Company Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Analyst Recommendations for Qiagen N.V. (NASDAQ:QGEN)

Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.